AI-powered tissue-specific digital twin with multi-modal patient data. Drug response predicted before a single experiment.
We capture primary patient cell biology, including tissue-specific microenvironments, immune systems, and extracellular matrix structures. This guarantees a human-relevant preclinical baseline.
Our deep learning architectures ingest multi-modal patient data, training disease models to simulate biological dynamics and response to drugs.
AI-powered simulations evaluate millions of patient twin variations, uncovering efficacy trends, toxicity windows, and molecular binding interactions before experimental testing begins.
We simulate dose-response behavior across millions of patient-specific digital twins, predicting efficacy, toxicity, and receptor binding affinity before a single tissue is bioprinted.